Vinorelbine (Navelbine Oral®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000453
English
Authors' recommendations:
Oral vinorelbine (Navelbine Oral®) is recommended for use within NHS Wales as a single agent (in line with current NICE recommendations for IV vinorelbine), for the treatment of advanced breast cancer stage III and IV relapsing after or refractory to an anthracycline-containing regimen.
Oral vinorelbine (Navelbine Oral®) should only be initiated by specialists experienced in the treatment of breast cancer.
Oral vinorelbine (Navelbine Oral®) should not presently be recommended for shared care.
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=89097&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Vinblastine
- Antineoplastic Agents, Phytogenic
- Breast Neoplasms
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.